Over the past 16 months, Chinese-domiciled biotechs have featured in roughly 6 of every 26 major pharma licensing and acquisition deals, accounting for nearly one-third of total headline value. Roughly half of those deals involve firms of U.S. origin, mostly involving M&A. Just under 30% involves licensing deals with Chinese-headquartered firms while the remainder involves…
How Dandelion Health’s multimodal dataset promises to shed light on GLP-1 research
Dandelion Health, the maker of a real-world data and clinical AI platform, has launched the first multimodal real-world clinical dataset focused on uncovering insights and opportunities related to GLP-1 receptor agonist drugs. The company describes the GLP-1 data library as “the first multimodal real-world clinical dataset” related to GLP-1 receptor agonists. The library is sourced…
Recurrent clinical trial events: Analyzing methodologies with cardiology examples
Cardiology trials often adopt composite endpoints that combine several events of clinical interest as the primary efficacy outcome. Time-to-first-event approaches follow the recommendations of regulatory agencies. But composite outcomes that only consider the first event are suboptimal for a chronic disease such as heart failure (HF), which is characterized by recurrent HF hospitalizations since repeat…


